Results from two, single-arm, multicenter, phase 2 trials, Study 206 (eribulin monotherapy in HER2− MBC) and Study 208 (combination eribulin plus trastuzumab in HER2+ MBC), as first-line treatment in patients with locally recurrent BC or MBC have been published (McIntyre et al. 2014; Wilks et al. 2014). The gene discussed is ERBB2; the disease is breast cancer.